💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Stiripentol

CHEMBL1983350 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
234.3 g/mol
LogP
3.6
Phase
4

Stiripentol is a structurally unique antiepileptic agent that acts through multiple mechanisms including potentiation of GABA-A receptor function, inhibition of voltage-dependent sodium channels, and inhibition of cytochrome P450 enzymes (CYP2C19 and CYP3A4), used for the adjunctive treatment of seizures in Dravet syndrome (severe myoclonic epilepsy of infancy) in patients also receiving clobazam and valproate. By inhibiting the metabolism of clobazam to its active metabolite norclobazam, and by directly potentiating GABAergic inhibition, it provides synergistic anticonvulsant effects. It is an orphan drug specifically indicated for this pharmacogenomically defined syndrome.

Молекулярная масса

234,2900 g/mol

LogP

3,60

TPSA

38,70 Ų

Правило пяти Липинского

Соответствует

Терапевтические области

Epilepsy

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC(C)(C)C(O)/C=C/c1ccc2c(c1)OCO2

                

                

                
                

                    
InChI

                    
InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3/b7-5+

                

                

                

                    
                    

                        
Molecular Formula

                        
C14H18O3

                    

                    
                    

                        
HBD / HBA

                        
1 / 3

                    

                    
                    

                        
Вращаемые Связи

                        
3

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
17

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
Stiripentol is a structurally unique antiepileptic agent that acts through multiple mechanisms including potentiation of GABA-A receptor function, inhibition of voltage-dependent sodium channels, and inhibition of cytochrome P450 enzymes (CYP2C19 and CYP3A4), used for the adjunctive treatment of seizures in Dravet syndrome (severe myoclonic epilepsy of infancy) in patients also receiving clobazam and valproate. By inhibiting the metabolism of clobazam to its active metabolite norclobazam, and by directly potentiating GABAergic inhibition, it provides synergistic anticonvulsant effects. It is an orphan …

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Stiripentol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1983350.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5311454.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.